Jazz fibromyalgia drug nixed by FDA panel

An FDA advisory panel meeting Friday poured cold water on Jazz Pharmaceuticals' bid to market JZP-6 as a treatment for fibromyalgia as the drug contains a form of gamma hydroxybutyrate (GHB), the so-called "date rape" drug. Jazz's narcolepsy drug Xyrem contains the same active ingredient as the proposed fibromyalgia treatment. Panelists figured that it would be too risky to make JZP-6 available to a population of up to 12 million people in the U.S. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.